Cargando…
In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2
Failure in the treatment of P. aeruginosa, due to its broad spectrum of resistance, has been associated with increased patient mortality. One alternative approach for infection control is quorum quenching which was found to decrease virulence of such pathogen. In this study, the efficiency of a reco...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316526/ https://www.ncbi.nlm.nih.gov/pubmed/34313869 http://dx.doi.org/10.1186/s13568-021-01269-7 |
_version_ | 1783729867924176896 |
---|---|
author | Sakr, Masarra M. Elkhatib, Walid F. Aboshanab, Khaled M. Mantawy, Eman M. Yassien, Mahmoud A. Hassouna, Nadia A. |
author_facet | Sakr, Masarra M. Elkhatib, Walid F. Aboshanab, Khaled M. Mantawy, Eman M. Yassien, Mahmoud A. Hassouna, Nadia A. |
author_sort | Sakr, Masarra M. |
collection | PubMed |
description | Failure in the treatment of P. aeruginosa, due to its broad spectrum of resistance, has been associated with increased patient mortality. One alternative approach for infection control is quorum quenching which was found to decrease virulence of such pathogen. In this study, the efficiency of a recombinant Ahl-1 lactonase formulated as a hydrogel was investigated to control the infection of multidrug resistant (MDR) P. aeruginosa infected burn using a murine model. The recombinant N-acylhomoserine lactonase (Ahl-1) was formulated as a hydrogel. To test its ability to control the infection of MDR P. aeruginosa, a thermal injury model was used. Survival rate, and systemic spread of the infection were evaluated. Histopathological examination of the animal dorsal skin was also done for monitoring the healing and cellular changes at the site of infection. Survival rate in the treated group was 100% relative to 40% in the control group. A decrease of up to 3 logs of bacterial count in the blood samples of the treated animals relative to the control group and a decrease of up to 4 logs and 2.3 logs of bacteria in lung and liver samples, respectively were observed. Histopathological examination revealed more enhanced healing process in the treated group. Accordingly, by promoting healing of infected MDR P. aeruginosa burn and by reducing systemic spread of the infection as well as decreasing mortality rate, Ahl-1 hydrogel application is a promising strategy that can be used to combat and control P. aeruginosa burn infections. |
format | Online Article Text |
id | pubmed-8316526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-83165262021-08-02 In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 Sakr, Masarra M. Elkhatib, Walid F. Aboshanab, Khaled M. Mantawy, Eman M. Yassien, Mahmoud A. Hassouna, Nadia A. AMB Express Original Article Failure in the treatment of P. aeruginosa, due to its broad spectrum of resistance, has been associated with increased patient mortality. One alternative approach for infection control is quorum quenching which was found to decrease virulence of such pathogen. In this study, the efficiency of a recombinant Ahl-1 lactonase formulated as a hydrogel was investigated to control the infection of multidrug resistant (MDR) P. aeruginosa infected burn using a murine model. The recombinant N-acylhomoserine lactonase (Ahl-1) was formulated as a hydrogel. To test its ability to control the infection of MDR P. aeruginosa, a thermal injury model was used. Survival rate, and systemic spread of the infection were evaluated. Histopathological examination of the animal dorsal skin was also done for monitoring the healing and cellular changes at the site of infection. Survival rate in the treated group was 100% relative to 40% in the control group. A decrease of up to 3 logs of bacterial count in the blood samples of the treated animals relative to the control group and a decrease of up to 4 logs and 2.3 logs of bacteria in lung and liver samples, respectively were observed. Histopathological examination revealed more enhanced healing process in the treated group. Accordingly, by promoting healing of infected MDR P. aeruginosa burn and by reducing systemic spread of the infection as well as decreasing mortality rate, Ahl-1 hydrogel application is a promising strategy that can be used to combat and control P. aeruginosa burn infections. Springer Berlin Heidelberg 2021-07-27 /pmc/articles/PMC8316526/ /pubmed/34313869 http://dx.doi.org/10.1186/s13568-021-01269-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Sakr, Masarra M. Elkhatib, Walid F. Aboshanab, Khaled M. Mantawy, Eman M. Yassien, Mahmoud A. Hassouna, Nadia A. In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 |
title | In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 |
title_full | In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 |
title_fullStr | In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 |
title_full_unstemmed | In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 |
title_short | In vivo evaluation of a recombinant N-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with MDR Pseudomonas aeruginosa clinical isolate, CCASUP2 |
title_sort | in vivo evaluation of a recombinant n-acylhomoserine lactonase formulated in a hydrogel using a murine model infected with mdr pseudomonas aeruginosa clinical isolate, ccasup2 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316526/ https://www.ncbi.nlm.nih.gov/pubmed/34313869 http://dx.doi.org/10.1186/s13568-021-01269-7 |
work_keys_str_mv | AT sakrmasarram invivoevaluationofarecombinantnacylhomoserinelactonaseformulatedinahydrogelusingamurinemodelinfectedwithmdrpseudomonasaeruginosaclinicalisolateccasup2 AT elkhatibwalidf invivoevaluationofarecombinantnacylhomoserinelactonaseformulatedinahydrogelusingamurinemodelinfectedwithmdrpseudomonasaeruginosaclinicalisolateccasup2 AT aboshanabkhaledm invivoevaluationofarecombinantnacylhomoserinelactonaseformulatedinahydrogelusingamurinemodelinfectedwithmdrpseudomonasaeruginosaclinicalisolateccasup2 AT mantawyemanm invivoevaluationofarecombinantnacylhomoserinelactonaseformulatedinahydrogelusingamurinemodelinfectedwithmdrpseudomonasaeruginosaclinicalisolateccasup2 AT yassienmahmouda invivoevaluationofarecombinantnacylhomoserinelactonaseformulatedinahydrogelusingamurinemodelinfectedwithmdrpseudomonasaeruginosaclinicalisolateccasup2 AT hassounanadiaa invivoevaluationofarecombinantnacylhomoserinelactonaseformulatedinahydrogelusingamurinemodelinfectedwithmdrpseudomonasaeruginosaclinicalisolateccasup2 |